4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Hernia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 107 ongoing clinical trials involving Hernia
Of the 107 trials,51 trials are in Phase II
Furthermore, 20 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Hernia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Hernia, a Gastrointestinal condition. The largest number of ongoing clinical trials for Hernia is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Hernia-related drug trials.

Mansoura University and Seikagaku Corp : The leading ongoing Hernia related clinical trial sponsors

Mansoura University and Seikagaku Corp are the top sponsors for Hernia-related ongoing clinical trials.

Innocoll Holdings Ltd, Affiliated Hospital of Xuzhou Medical University, Indira Gandhi Institute of Medical Sciences, Netherlands Organisation for Health Research and Development, and Heron Therapeutics Inc are among other notable clinical trial sponsors involved in Hernia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Hernia

Condoliase (Hernicore/ SI-6603) is solely the key marketed drug involving Hernia.

Condoliase (Hernicore/ SI-6603) is an recombinant enzyme, a formulation of chondroitinase ABC produced from bacteria. It functions via Glycosaminoglycan Inhibitor mechanism of action. Condoliase is formulated as injectable solution for intradiscal route of administration. It is indicated for the treatment of lumbar disc herniation in adults. It is under development for the treatment of lumbar disc herniation. Condoliase was first approved in 2018 and is marketed solely in Japan by Kaken Pharmaceutical Co Ltd.